BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives Positive FDA Review Letter Supporting Ketamine ANDA Progress April 23, 2026 depression ONLY AVAILABLE IN PAID PLANS. Originally reported by financialcontent. Read more Source: https://www.financialcontent.com/article/nnwire-2026-4-22-biomednewsbreaks-nrx-pharmaceuticals-inc-nasdaq-nrxp-receives-positive-fda-review-letter-supporting-ketamine-anda-progress
